Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615243 | 0.93 | LOXL2 (0.30) | — | |
| SCHEMBL15267408 | 0.92 | — | — | |
| SCHEMBL1764910 | 0.92 | TOP2A (0.34) | — | |
| SCHEMBL1933709 | 0.90 | — | — | |
| SCHEMBL6301535 | 0.90 | ALDH1A1 (0.40) | — | |
| SCHEMBL19022293 | 0.88 | TACR1 (0.33) | — | |
| SCHEMBL791614 | 0.88 | IDO1 (0.42) | — | |
| SCHEMBL22340028 | 0.87 | CYP19A1 (0.39) | — | |
| SCHEMBL546163 | 0.85 | IDO1 (0.49) | — | |
| SCHEMBL22198892 | 0.82 | BACE1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341103-B | Aminoguanhydrazones as retrograde transport stabilizers useful in the treatment of neurological diseases | 圣拉斐尔医院有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20220213030-A1 | AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES | OSPEDALE SAN RAFFAELE SRL (IT) | 2022-07-07 | — | — | US | disclosed |
| CN-114341103-A | Aminoguanidinohydrazones as reverse transporter stabilizers useful for the treatment of neurological disorders | 圣拉斐尔医院有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3947344-A1 | AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES | Ospedale San Raffaele Srl (IT) | 2022-02-09 | — | — | EP | disclosed |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3778601-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3189056-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-9974867-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170340749-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | DUT 2387/4885 |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | DUT 2387/4885 |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | DUT 2387/4885 |
| US-20170340749-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | DUT 2662/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | DUT 2387/4885 |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | DUT 2387/4885 |
| US-20220213030-A1 | AMINOGUANIDINE HYDRAZONES AS RETROMER STABILIZERS USEFUL FOR TREATING NEUROLOGICAL DISEASES | PARK7, HTT, HRH1 | DUT 3394/4885 |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | DUT 2387/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | DUT 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.